title: [Effect of RAD18-siRNA on proliferation and chemotherapy sensitivity of human esophageal squamous cell carcinoma ECA-109 cells].
abstract: Objective:To investigate the effect of RAD18-siRNA on cell proliferation and chemotherapy sensitivity of esophageal squamous cell carcinoma (ESCC) ECA-109 cells.Methods:RAD18-siRNA was transfected into human ECA-109 cells by Lipofectamine 3000. Quantitative PCR and Western blot were performed to detect RAD18 and CyclinD1 expression; CCK-8 assay was used to determine cell proliferation and chemotherapy drug sensitivity; flow cytometry was used to determine cell cycle. Correlation between RAD18 and CyclinD1 mRNA expression was analyzed by Pearson's correlation.Results:Compared with non-transfected cells, the expression of RAD18 in RAD18-siRNA group was significantly decreased (P<0.05). The cell proliferation was inhibited (P<0.05) and the cell number of G1 phase was increased, G2/M phase cells decreased (P<0.05) in RAD18-siRNA group. After treatment with different concentrations of cisplatin or 5-FU, the survival rate of the two cell groups was reduced (allP<0.05), and the IC50 of RAD18-siRNA group was significantly lower than that of non-transfected group (P<0.05). The mRNA expression of RAD18 was positively correlated with CyclinD1 expression in ESCC tissues(r=0.478,P<0.01).Conclusion:Down-regulated expression of RAD18 can decrease the cell proliferation and increase chemo-sensitivity of ESCC cells, and CyclinD1 may participate in the process.
authors.affiliation: Department of Radio-Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310020, China;Department of Radio-Oncology, Ningbo First Hospital, Ningbo 315010, China.
authors.forename: Pengrong
authors.initials: P
authors.lastname: Lou
authors.affiliation: Department of Radio-Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310020, China. sunxiaonan@hotmail.com.
authors.forename: Xiaonan
authors.initials: X
authors.lastname: Sun
authors.affiliation: Department of Radio-Oncology, Suzhou Municipal Hospital, Nanjing Medical University, Suzhou 215001, China. zhoujundong330@163.com.
authors.forename: Jundong
authors.initials: J
authors.lastname: Zhou
authors.affiliation: Suzhou Cancer Center Core Laboratory, Suzhou Municipal Hospital, Nanjing Medical University, Suzhou 215001, China.
authors.forename: Shitao
authors.initials: S
authors.lastname: Zou
mesh_terms: D000277:Adjuvants, Pharmaceutic / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000503:physiopathology*; D002453:Cell Cycle; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D002945:Cisplatin / Q000494:pharmacology; D019938:Cyclin D1 / Q000187:drug effects / Q000235:genetics; D004268:DNA-Binding Proteins / Q000008:administration & dosage / Q000494:pharmacology*; D015536:Down-Regulation / Q000187:drug effects / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D004357:Drug Synergism; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D000077277:Esophageal Squamous Cell Carcinoma; D005472:Fluorouracil / Q000494:pharmacology; D016193:G1 Phase / Q000187:drug effects; D016195:G2 Phase / Q000187:drug effects; D006801:Humans; D008677:Metaphase / Q000187:drug effects; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000494:pharmacology*; D014162:Transfection; D044767:Ubiquitin-Protein Ligases / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000277:Adjuvants, Pharmaceutic; C530104:CCND1 protein, human; D004268:DNA-Binding Proteins; C485954:RAD18 protein, human; D034741:RNA, Small Interfering; D019938:Cyclin D1; D044767:Ubiquitin-Protein Ligases; D002945:Cisplatin; D005472:Fluorouracil